Axcella Health Inc. (NASDAQ:AXLA) is set to announce third quarter earning results on Thursday 12th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AXLA to report 3Q20 loss of $ 0.41 per share.
For the full year, analysts anticipate loss of $ 1.93 per share bottom line.
Stock Performance
Shares of Axcella Health Inc. traded up $ 0.29 or 5.75 percent on Wednesday, reaching $ 5.33 with volume of 109.70 thousand shares. Axcella Health Inc. has traded high as $ 5.35 and has cracked $ 4.84 on the downward trend
The closing price of $ 5.33, representing a 124.00 % increase from the 52 week low of $ 2.25 and a 34.8 % decrease over the 52 week high of $ 7.73.
The company has a market capital of $ 194.26 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 25th September 2020, initiated by B. Riley at Buy rating, with $ 14.00 target price.
Conference Call
Axcella Health Inc. will be hosting a conference call at 8:30 AM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (866) 652-5200 Toll Free or (412) 317-6060 (International) in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.axcellahealth.com
Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.
